There’s a lot of longer-term benefits we think will come that way. Our €“ in the agent business itself, MI agents are about a third of volume, about two-thirds is contrast imaging agents used in the X-ray equipment. But we believe that’s going to be a growing area with again newer capabilities coming out of the pharma space that we play a critical role in helping do the diagnostics. On the device side itself, we’ve got a great platform, a great team. We do some outstanding work here in the United States as well as in Israel on these devices, probably one of the deeper expertise capabilities on different technologies, whether they be BGO or LSO, different types of PET/CT detectors as well as the CZT expertise we have within our MI devices.
And combined between PET and MI, we think that this is going to be continuing growth area. It’s still at this point compared to MR and CT, a more moderate sized business. But again, with the rise of these new technologies and giving an example of an aging comes out that needs this type a follow-up to actually assess either amyloid beta plaque or other capabilities, we believe our MI technologies out in the industry will really play a key role in helping drive that diagnosis. And then down the road can even play a larger role in the therapy process either dose or delivery of agents. So, Helmut, you may want to comment a little bit on the pricing question.
Helmut Zodl: Yes. Thanks, Pete. So Ed, on price, we’re quite happy with the progress we’ve been making on price throughout the year. So we started really tracking price on orders last year. So we have both a management system that looks at the orders, but also looks at how much price we have in sales. And in sales, since the second quarter, we have price in our sales or in revenue. It started at the low single-digit. It improved as it went through the third quarter. And we are now for some of our modalities in the mid single-digit level what we are seeing on price. So we were quite happy about how we performed, and we also have good visibility on price for this in our backlog. So we already know what is going to happen and ship here over the next quarters and how much price is in the backlog.
Carolynne Borders: Michelle, we’ll take our next question.
Operator: Thank you. Our next question comes from Vijay Kumar with Evercore. Your line is open.
Vijay Kumar: Hey, guys. Congratulations on a nice finish here and thanks for taking my question.
Peter Arduini: Thank you.
Vijay Kumar: Maybe my first question here on the guidance assumptions here. Peter, can you talk about any trends and cancellation rates or cadence that we need to be aware of? When you look at the 5% or 7%, what is pricing? How much of that 5% or 7% do you have visibility given the backlog and the book-to-bill ratios here?
Peter Arduini: Yes, Vijay. Look, good question. We have some actually quite good visibility at this point with carrying a little bit larger backlog than we normally do. One of the advantages of that is we actually have greater visibility out into the distance about what the deals look like, what the margin is on the deal, the timing thereof. And one of the things our operating teams in each of the segments have done a very nice job is actually speaking with customers and getting all the installed base products planned out as far as we can go, which is in many cases, a couple of quarters out, which is longer than we have historically done, but we did that purposely just based on some of the questions within the macro environment.